|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1B
|
|
pubmed:dateCreated |
2000-5-8
|
|
pubmed:abstractText |
Doxorubicin remains one of the few drugs with consistent single agent activity in advanced Soft Tissue Sarcomas (STS), with a demonstrated dose-response relationship. Liposomal-encapsulated Doxorubicin (LED) has been shown to be at least as active as free doxorubicin in experimental models, and phase I and II human studies indicate that this novel strategy of drug delivery my have less myocardial toxicity. Few clinical trials in adult STS have been published until now, with disappointing and often contrasting results.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
485-91
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10769710-Adult,
pubmed-meshheading:10769710-Aged,
pubmed-meshheading:10769710-Alopecia,
pubmed-meshheading:10769710-Antibiotics, Antineoplastic,
pubmed-meshheading:10769710-Cardiomyopathies,
pubmed-meshheading:10769710-Disease-Free Survival,
pubmed-meshheading:10769710-Doxorubicin,
pubmed-meshheading:10769710-Drug Administration Schedule,
pubmed-meshheading:10769710-Drug Carriers,
pubmed-meshheading:10769710-Drug Compounding,
pubmed-meshheading:10769710-Drug Eruptions,
pubmed-meshheading:10769710-Drug Resistance, Neoplasm,
pubmed-meshheading:10769710-Female,
pubmed-meshheading:10769710-Humans,
pubmed-meshheading:10769710-Infusions, Intravenous,
pubmed-meshheading:10769710-Italy,
pubmed-meshheading:10769710-Life Tables,
pubmed-meshheading:10769710-Liposomes,
pubmed-meshheading:10769710-Male,
pubmed-meshheading:10769710-Middle Aged,
pubmed-meshheading:10769710-Neoplasm Metastasis,
pubmed-meshheading:10769710-Neutropenia,
pubmed-meshheading:10769710-Remission Induction,
pubmed-meshheading:10769710-Sarcoma,
pubmed-meshheading:10769710-Soft Tissue Neoplasms,
pubmed-meshheading:10769710-Survival Analysis,
pubmed-meshheading:10769710-Treatment Outcome,
pubmed-meshheading:10769710-Ventricular Function, Left
|
|
pubmed:articleTitle |
Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
|
|
pubmed:affiliation |
Department of Medical Oncology, University of Genoa-National Institute for Cancer Research, Italy. toma@ermes.cba.unige.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
